Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
AssigneeMedImmune, LLC
InventorsHerren Wu, Changshou Gao
Life of this patent
Estimating the term…
Loading patent…
AssigneeMedImmune, LLC
InventorsHerren Wu, Changshou Gao
Estimating the term…
The present invention relates to novel Fc variants of antibodies that immunospecifically binds to Integrin αvβ3. The Fc variants comprise a variable region that immunospecifically binds to Integrin αvβ3 and a Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants of an antibody that immunospecifically binds to Integrin αvβ3, particularly for therapeutic purposes.
An antibody that immunospecifically binds to Integrin αvβ3 comprising an IgG1 Fc region, wherein the Fc region comprises at least the high effector function amino acid residue 332E, as numbered by the EU index as set forth in Kabat, wherein the antibody comprising at least the high effector function amino acid residue 332E has an altered binding affinity for one or more FcγRs as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.
Dependencies are inferred from the claim text.